Articoli correlati a Biosimilars: A New Generation of Biologics
‘Biosimilars’ are copies of biological medicinal products no longer protected by certification. Detailing new EU legal and regulatory frameworks on biosimilars, this book also analyzes their safety, marketing, and funding, and includes a section on US rules.
Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.
L'autore:
Jean-Louis Prugnaud is a pharmacist, former head of pharmacy department at Saint-Antoine Hospital, Paris, France. He is Member of the French Commission of drugs’ distribution authorization, President of the Commission of gene and cellular therapy and President of the pharmaceutical working group on biological and biothechnological drugs. Jean-Hugues Trouvin works at AFSSAPS (French health products safety agency) and at the pharmaceutical and biological sciences department at the Paris Descartes University in Paris, France. Preface: Christian K. Schneider is Chairman, CHMP of the Similar Biological (Biosimilar) Medicinal Products Working Party (BMWP), member of the European Medicines Agency( London, United Kingdom) and works at the Paul-Ehrlich-Institut, Federal Agency for Sera and Vaccines (Langen, Germany) and at the Centre for Experimental and Clinical Infection Research (Hannover, Germany).
Contenuti:
Preface: Biosimilars – a philosophy?.- Foreword.- 1. Biosimilars characteristics.- Introduction : from generics to biosimilars.- Definitions.- Complexity of biologics and examples.- Conclusion.- 2. From the biosimilar concept to the Marketing Approval. –Introduction.- Definition of biosimilars.- Pharmaceutical approval’s framework.- Quality control approach.- Non clinical and clinical aspects.- Recommendations in onco-hematology.- Other recommendations.- Conclusion.- 3. Immunogenicity.- Introduction.- Immune mechanisms.- Usual immune response.- Immunologic tolerance breakdown response.- Factors influencing immunogenicity.- Case of monoclonal antibodies.- Conclusion.- 4. Substitution and interchangeability.- Introduction.- Generics and biosimilars’ substitution.- What about biosimilar medicinal products ?.- Interchangeability: suggested definition.- Biosimilars’ interchangeability and conditions to be implemented.- Interchangeability practices.- Conclusion.- 5. Onco-hematologist point of view –GCSFcase.- Biosimilars.- Conclusion.- 6. The oncologist‘s point of view.- Introduction.- Erythropoiesis-stimulating Agents (ESA).- Biosimilars.- Conclusion.- 7. Challenges posed by biosimilars: who is responsible for cost and risk management.- Introduction.- General information on cost management.- Savings linked to the purchase of biosimilars.- General information on risk management responsibility.- Conclusion.
Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.
- EditoreSpringer
- Data di pubblicazione2014
- ISBN 10 2817805143
- ISBN 13 9782817805146
- RilegaturaCopertina flessibile
- Numero edizione1
- Numero di pagine108
- RedattorePrugnaud Jean-Louis, Trouvin Jean-Hugues
Compra nuovo
Scopri di più su questo articolo
EUR 122,81
Spese di spedizione:
GRATIS
In U.S.A.
I migliori risultati di ricerca su AbeBooks
Immagini fornite dal venditore
Biosimilars: A New Generation of Biologics [FRENCH LANGUAGE - Paperback ]
Da:
Valutazione libreria
Descrizione libro Soft Cover. Condizione: new. Codice articolo 9782817805146
Compra nuovo
EUR 122,81
Convertire valuta
Foto dell'editore
Biosimilars: A New Generation of Biologics
Da:
Valutazione libreria
Descrizione libro Condizione: New. Codice articolo ABLIING23Mar3012140348836
Compra nuovo
EUR 130,56
Convertire valuta
Foto dell'editore
Biosimilars : A New Generation of Biologics
Print on Demand
Da:
Valutazione libreria
Descrizione libro Condizione: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Codice articolo ria9782817805146_lsuk
Compra nuovo
EUR 138,02
Convertire valuta
Immagini fornite dal venditore
Biosimilars
Editore:
Springer Paris Dez 2014
(2014)
ISBN 10: 2817805143
ISBN 13: 9782817805146
Nuovo
Taschenbuch
Quantità: 2
Da:
Valutazione libreria
Descrizione libro Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the 'generic rule' valid for small chemical entities. In response, a dedicated regulation was issued in the European Union. It is based on the concept of 'biological medicinal products similar to a biological reference product', or 'biosimilars'. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature. This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context. 108 pp. Englisch. Codice articolo 9782817805146
Compra nuovo
EUR 128,39
Convertire valuta
Immagini fornite dal venditore
Biosimilars
Editore:
Springer Paris
(2014)
ISBN 10: 2817805143
ISBN 13: 9782817805146
Nuovo
Brossura
Quantità: > 20
Da:
Valutazione libreria
Descrizione libro Condizione: New. Codice articolo 4315316
Compra nuovo
EUR 107,09
Convertire valuta
Immagini fornite dal venditore
Biosimilars : A New Generation of Biologics
Editore:
Springer Paris
(2014)
ISBN 10: 2817805143
ISBN 13: 9782817805146
Nuovo
Taschenbuch
Quantità: 1
Da:
Valutazione libreria
Descrizione libro Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the 'generic rule' valid for small chemical entities. In response, a dedicated regulation was issued in the European Union. It is based on the concept of 'biological medicinal products similar to a biological reference product', or 'biosimilars'. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature. This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context. Codice articolo 9782817805146
Compra nuovo
EUR 129,93
Convertire valuta
Foto dell'editore
Biosimilars: A New Generation of Biologics
Editore:
Springer Verlag
(2014)
ISBN 10: 2817805143
ISBN 13: 9782817805146
Nuovo
Paperback
Quantità: 2
Da:
Valutazione libreria
Descrizione libro Paperback. Condizione: Brand New. 1st edition. 87 pages. 9.00x6.00x0.25 inches. In Stock. Codice articolo x-2817805143
Compra nuovo
EUR 156,14
Convertire valuta